Spyre Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, null, 41.85, 108.76 ], "ebit_estimate": [ -281.32, -349.93, -399.52, -443.88, -451.15 ], "ebitda_estimate": [ -272.82, -341.61, -386.18, -481, -144.6 ], "net_income_estimate": [ -267.1, -306.42, -358.87, -410.25, -424.37 ], "per_share_eps_estimate": [ -2.97, -3.33, -3.91, -4.17, -4.29 ], "eps_nri_estimate": [ -3.02, -3.23, -3.74, -4.21, -4.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 11.18, 7.46, 6.2, 4.41, 3.85 ], "pretax_income_estimate": [ -272.29, -313.05, -368.9, -420.1, -431.6 ], "operating_cash_flow_per_share_estimate": [ -2.71, -3.38, -3.98, -4.32, -1.29 ], "roa_estimate": [ -26.4, -33.4, -50.4, -68.2, -23.2 ], "roe_estimate": [ -28.61, -31.19, -49.83, -84.3, -30.4 ], "gross_margin_estimate": [ null, null, null, null, 85 ], "operating_cash_flow_estimate": [ -212.87, -265.5, -312.63, -339.33, -101.33 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -21.89, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -24.08, "future_eps_nri_estimate_growth": -21.89, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -24.04, "future_ebitda_estimate_growth": -22.86, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -30.37, "future_pretax_income_estimate_growth": -31.48, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": -30.6, "future_roe_estimate_growth": -18.87, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -15.63 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -74.37, -77.36, -80.58, -85.85, -88.5, -91.93, -94.15 ], "ebitda_estimate": [ -70.54, -74.69, -77.38, -84.8, null, null, null ], "net_income_estimate": [ -68.98, -69.85, -67.49, -76.47, -81.75, -85.33, -87.78 ], "per_share_eps_estimate": [ -0.73, -0.67, -0.76, -0.85, -0.87, -0.9, -0.91 ], "eps_nri_estimate": [ -0.76, -0.75, -0.72, -0.82, -0.87, -0.9, -0.91 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -70.2, -70.53, -68.25, -76.99, -83.17, -86.87, -89.03 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -32.77, -21.53, -16.9, -26.54, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -21.89, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -24.08, "future_eps_nri_estimate_growth": -21.89, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -24.04, "future_ebitda_estimate_growth": -22.86, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -30.37, "future_pretax_income_estimate_growth": -31.48, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": -30.6, "future_roe_estimate_growth": -18.87, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -15.63 }